Author Index

Adler, A. *see* Lurie, H., 163
Ajika, K. *see* Okutomi, T., 275
Ajitsu, T. *see* Miyake, Y., 37
Aldrich, W. *see* Rinehart, J.J., 133
Amox, D. *see* Dillman, R.O., 81
Arai, K. *see* Okutomi, T., 275
Avner, Barry *see* Ogden, J.R., 170; Oldham, R.K., 103
Avner, Belina *see* Oldham, R.K., 103; Orr, D., 229
Azuma, I. *see* Saiki, I., 261

Barnett, M.J. *see* Oliver, R.T.D., 14
Bartholomew, M.J. *see* Romano, P.J., 208
Bartsch, H.H., Nagel, G.A., Mull, R., Flener, R. and Pfizenmaier, K.: Phase 1 study of recombinant human necrosis factor-alpha in patients with advanced malignancies, 21
Beauregard, J.C. *see* Dillman, R.O., 81
Beidler, D. *see* Dillman, R.O., 250
Birch, R. *see* Oldham, R.K., 103; Orr, D., 229; West, W.H., 268
Blalock, J.E. *see* Stanton, G.J., 305
Brattia, M. *see* Marth, C., 140
Bystryn, J-C. *see* Johnston, D., 218

Carpenter, R.H. *see* Tizard, I.R., 290
Chang, L. *see* Gazitt, Y., 328
Chao, T-Y, Ohnishi, H. and Chu, T. Ming: Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin, 318
Chu, T. Ming *see* Chao, T-Y, 318
Clemmesen, J.: Antitumor effect of lactobacilli substances: "*L. bulgaricus* effect," 279
Coggin, J.H. *see* Hester, R.B., 244
Coggin, J.H., Jr.: Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas, 223
Cohen, E.P., Lazda, V.A., Schade, S.G., Kennedy, J.L., Kaufman, E.R. and Hagen, K.L.: Report of two cases of acute myelogenous leukemia immunized with autologous leukemia-derived hybrid cells, 86
Collino, C.E. *see* Oliver, R.T.D., 43
Colton, C.K. *see* Murphy, R.M., 186
Cox, J.W., Jr. *see* Schulof, R.S., 30

Davidovitz, J. *see* Lurie, H., 163
Daxenbichler, G. *see* Marth, C., 140
Dillman, R.O., Beauregard, J.C., Jamieson, M., Amox, D. and Halpern, S.E.: Toxicities associated with monoclonal antibody infusions in cancer patients, 81
Dillman, R.O., Johnson, D.E., Ogden, J. and Beidler, D.: Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates, 250
Dillman, R.O., Koziol, J.A. and Shawler, D.L.: Mathematical modeling for antibody therapy in the setting of antigenic modulation, 46
Dillman, R.O. *see* Glassy, M.C., 7
Dobashi, K. *see* Okutomi, T., 275
Downing, M.R. *see* Romano, P.J., 208
Dupere, S. *see* Orr, D., 229

Fenig, E. *see* Lurie, H., 163
Flener, R. *see* Bartsch, H.H., 21

Gangadharan, M. *see* Nerkar, D.P., 152
Gangavalli, A. *see* Gazitt, Y., 297; Gazitt, Y., 328
Gazitt, Y., Gangavalli, A. and Thurman, G.B.: Induction of surface marker changes and monoclonal idiotypic immunoglobulin secretion in lymphoma/leukemia cells: Comparative study with interleukin-1, interleukin-2, interleukin-4, 8-bromo-guanosine, pokeweed mitogen, and tetradecanoyl phorbol-13-acetate, 297
Gazitt, Y., He, Y-J, Chang, L., Gangavalli, A., Hubbard, W.J., Oldham, R.K.: Establishment and characterization of a malignant lymphoid cell line from a chronic lymphocytic leukemia patient, 328
Geidenberger, C. *see* Rinehart, J.J., 133
Giudice, G. *see* Romano, P.J., 208
Glassy, M.C., Dillman, R.O.: Molecular biotherapy with human monoclonal antibodies, 7

Hagen, K.L. *see* Cohen, E.P., 86
Halpern, S.E. *see* Dillman, R.O., 81
Hamada, J-i. *see* Hosokawa, M., 74
Hanna, M.G. *see* Schulof, R.S., 30
Haranaka, K.: Traditional Chinese medicines as biological response modifiers, 175
see Satomi, N., 155
Haranaka, R. *see* Satomi, N., 155
Harvey, H.A. *see* Romano, P.J., 208
He, Y-J. *see* Gazitt, Y., 328
Hester, R.B. and Coggin, J.H., Jr.: Tumorigenic sublethal whole-body X-irradiation of RFM mice enhances cell-mediated cytotoxicity while transiently depressing T- and B-lymphocytes, 244
Higashi, N. *see* Saiki, I., 261
Hirata, S. *see* Okutomi, T., 275
Hix, W.R. *see* Schulof, R.S., 30
Hosokawa, M., Xu, Z-y, Morikawa, K., Hamada, J-i and Kobayashi, H.: Host immune responses to tumor cells augmented by bleomycin and their therapeutic effects on rat fibrosarcoma, 74
Hubbard, W.J. *see* Gazitt, Y., 328; Lewko, W.M., 256

Iimura, F. *see* Satomi, N., 155

Jamieson, M. *see* Dillman, R.O., 81
Johnson, D.E. *see* Dillman, R.O., 250
Johnston, D. and Bystryn, J-C: Immunogenicity and tumor protective activity of B16 melanoma vaccines, 218

Kaufman, E.R. *see* Cohen, E.P., 86
Kemp, M.C. *see* Tizard, I.R., 290
Kennedy, J.L. *see* Cohen, E.P., 86
Kloszewski, F. *see* Romano, P.J., 208
Kobayashi, H. *see* Hosokawa, M., 74
Koziol, J.A. *see* Dillman, R.O., 46
Kronke, M. *see* Schütze, S., 96
Kunda, S.A. *see* Ogden, J.R., 170

Lazda, V.A. *see* Cohen, E.P., 86
Leung, K. *see* Ogden, J.R., 170; Orr, D., 229
Lewis, M. *see* Oldham, R.K., 103; Orr, D., 229; West, W.H., 268
Lewko, W.M. *see* Pettengill, O.S., 122
Lewko, W.M., Nayak, S.K., Hubbard, W.J., Thurman, G.B. and Oldham, R.K.: Chemosensitivity testing in a tumor acquisition, propagation, and preservation program, 256
Liao, S-K. *see* Ogden, J.R., 170; Oldham, R.K., 103; Orr, D., 229
Lipton, A. *see* Romano, P.J., 208
Lloyd, R.E. *see* Stanton, G.J., 305
Lurie, H., Rakovsky, E., Fenig, E., Davidovitz, J. and Adler, A.: A pilot study of intraperitoneal recombinant interleukin-2 and *ex vivo* activated intracavitary lymphocytes in patients with malignant peritoneal spread: clinical aspects, 163

McAnalley, B.H. *see* Tizard, I.R., 290
McCall, C.A. *see* Warren, R.P., 145; Warren, R.P., 323
Mai, D. *see* Schulof, R.S., 30
Marshall, G.D. *see* West, W.H., 268
Marth, C., Brattia, M., Müller-Holzner, E., Mayer, I., Zech, J., Tabarelli, M. and Daxenbichler, G.: Modulation of secretion of human chorionic gonadotropin by biologic response modifiers on term placenta and choriocarcinoma cells, 140
Mayer, I. *see* Marth, C., 140
Mehta, A. *see* Oliver, R.T.D., 14
Miller, H.C. and Vito, C.: Action of a thymic cytokine TslF™ in reversing the autoimmune disease state of the MRL/lpr mouse, 213
Miller, R.M. *see* Oliver, R.T.D., 14
Mills, M. *see* Schulof, R.S., 30
Miyake, Y., Ajitsu, S., Yamashita, T. and Sendo, F.: Enhancement by recombinant interferon-γ of spontaneous tumor cytostasis by human neutrophils, 37
Mizuno, D. *see* Okutomi, T., 275
Morikawa, A. *see* Okutomi, T., 275
Morikawa, K. *see* Hosokawa, M., 74
Mull, R. *see* Bartsch, H.H., 21
Müller-Holzner, E. *see* Marth, C., 140
Murata, J. *see* Saiki, I., 261
Murphy, R.M., Colton, C.K. and Yarmush, M.L.: Staphylococcal protein A adsorption in neoplastic disease: analysis of physicochemical aspects, 186

Nagel, G.A. *see* Bartsch, H.H., 21
Nayak, S.K. *see* Lewko, W.M., 256
Nelson, A. *see* Schulof, R.S., 30
Nerkar, D.P. and Gangadharan, M.: Modification of L-asparaginase from *Erwinia carotovora* using human serum albumin, 152

Author Index

Adler, A. *see* Lurie, H., 163
Ajika, K. *see* Okutomi, T., 275
Ajitsu, T. *see* Miyake, Y., 37
Aldrich, W. *see* Rinehart, J.J., 133
Amox, D. *see* Dillman, R.O., 81
Arai, K. *see* Okutomi, T., 275
Avner, Barry *see* Ogden, J.R., 170; Oldham, R.K., 103
Avner, Belina *see* Oldham, R.K., 103; Orr, D., 229
Azuma, I. *see* Saiki, I., 261

Barnett, M.J. *see* Oliver, R.T.D., 14
Bartholomew, M.J. *see* Romano, P.J., 208
Bartsch, H.H., Nagel, G.A., Mull, R., Flener, R. and Pfizenmaier, K.: Phase 1 study of recombinant human necrosis factor-alpha in patients with advanced malignancies, 21
Beauregard, J.C. *see* Dillman, R.O., 81
Beidler, D. *see* Dillman, R.O., 250
Birch, R. *see* Oldham, R.K., 103; Orr, D., 229; West, W.H., 268
Blalock, J.E. *see* Stanton, G.J., 305
Brattia, M. *see* Marth, C., 140
Bystryn, J-C. *see* Johnston, D., 218

Carpenter, R.H. *see* Tizard, I.R., 290
Chang, L. *see* Gazitt, Y., 328
Chao, T-Y, Ohnishi, H. and Chu, T. Ming: Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin, 318
Chu, T. Ming *see* Chao, T-Y, 318
Clemmesen, J.: Antitumor effect of lactobacilli substances: "*L. bulgaricus* effect," 279
Coggin, J.H. *see* Hester, R.B., 244
Coggin, J.H., Jr.: Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas, 223
Cohen, E.P., Lazda, V.A., Schade, S.G., Kennedy, J.L., Kaufman, E.R. and Hagen, K.L.: Report of two cases of acute myelogenous leukemia immunized with autologous leukemia-derived hybrid cells, 86
Collino, C.E. *see* Oliver, R.T.D., 43
Colton, C.K. *see* Murphy, R.M., 186
Cox, J.W., Jr. *see* Schulof, R.S., 30

Davidovitz, J. *see* Lurie, H., 163
Daxenbichler, G. *see* Marth, C., 140
Dillman, R.O., Beauregard, J.C., Jamieson, M., Amox, D. and Halpern, S.E.: Toxicities associated with monoclonal antibody infusions in cancer patients, 81
Dillman, R.O., Johnson, D.E., Ogden, J. and Beidler, D.: Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates, 250
Dillman, R.O., Koziol, J.A. and Shawler, D.L.: Mathematical modeling for antibody therapy in the setting of antigenic modulation, 46
Dillman, R.O. *see* Glassy, M.C., 7
Dobashi, K. *see* Okutomi, T., 275
Downing, M.R. *see* Romano, P.J., 208
Dupere, S. *see* Orr, D., 229

Fenig, E. *see* Lurie, H., 163
Flener, R. *see* Bartsch, H.H., 21

Gangadharan, M. *see* Nerkar, D.P., 152
Gangavalli, A. *see* Gazitt, Y., 297; Gazitt, Y., 328
Gazitt, Y., Gangavalli, A. and Thurman, G.B.: Induction of surface marker changes and monoclonal idiotypic immunoglobulin secretion in lymphoma/leukemia cells: Comparative study with interleukin-1, interleukin-2, interleukin-4, 8-bromo-guanosine, pokeweed mitogen, and tetradecanoyl phorbol-13-acetate, 297
Gazitt, Y., He, Y-J, Chang, L., Gangavalli, A., Hubbard, W.J., Oldham, R.K.: Establishment and characterization of a malignant lymphoid cell line from a chronic lymphocytic leukemia patient, 328
Geidenberger, C. *see* Rinehart, J.J., 133
Giudice, G. *see* Romano, P.J., 208
Glassy, M.C., Dillman, R.O.: Molecular biotherapy with human monoclonal antibodies, 7

Hagen, K.L. *see* Cohen, E.P., 86
Halpern, S.E. *see* Dillman, R.O., 81
Hamada, J-i. *see* Hosokawa, M., 74
Hanna, M.G. *see* Schulof, R.S., 30
Haranaka, K.: Traditional Chinese medicines as biological response modifiers, 175
see Satomi, N., 155
Haranaka, R. *see* Satomi, N., 155
Harvey, H.A. *see* Romano, P.J., 208
He, Y-J. *see* Gazitt, Y., 328
Hester, R.B. and Coggin, J.H., Jr.: Tumorigenic sublethal whole-body X-irradiation of RFM mice enhances cell-mediated cytotoxicity while transiently depressing T- and B-lymphocytes, 244
Higashi, N. *see* Saiki, I., 261
Hirata, S. *see* Okutomi, T., 275
Hix, W.R. *see* Schulof, R.S., 30
Hosokawa, M., Xu, Z-y, Morikawa, K., Hamada, J-i and Kobayashi, H.: Host immune responses to tumor cells augmented by bleomycin and their therapeutic effects on rat fibrosarcoma, 74
Hubbard, W.J. *see* Gazitt, Y., 328; Lewko, W.M., 256

Iimura, F. *see* Satomi, N., 155

Jamieson, M. *see* Dillman, R.O., 81
Johnson, D.E. *see* Dillman, R.O., 250
Johnston, D. and Bystryn, J-C: Immunogenicity and tumor protective activity of B16 melanoma vaccines, 218

Kaufman, E.R. *see* Cohen, E.P., 86
Kemp, M.C. *see* Tizard, I.R., 290
Kennedy, J.L. *see* Cohen, E.P., 86
Kloszewski, F. *see* Romano, P.J., 208
Kobayashi, H. *see* Hosokawa, M., 74
Koziol, J.A. *see* Dillman, R.O., 46
Kronke, M. *see* Schütze, S., 96
Kunda, S.A. *see* Ogden, J.R., 170

Lazda, V.A. *see* Cohen, E.P., 86
Leung, K. *see* Ogden, J.R., 170; Orr, D., 229
Lewis, M. *see* Oldham, R.K., 103; Orr, D., 229; West, W.H., 268
Lewko, W.M. *see* Pettengill, O.S., 122
Lewko, W.M., Nayak, S.K., Hubbard, W.J., Thurman, G.B. and Oldham, R.K.: Chemosensitivity testing in a tumor acquisition, propagation, and preservation program, 256
Liao, S-K. *see* Ogden, J.R., 170; Oldham, R.K., 103; Orr, D., 229
Lipton, A. *see* Romano, P.J., 208
Lloyd, R.E. *see* Stanton, G.J., 305
Lurie, H., Rakovsky, E., Fenig, E., Davidovitz, J. and Adler, A.: A pilot study of intraperitoneal recombinant interleukin-2 and *ex vivo* activated intracavitary lymphocytes in patients with malignant peritoneal spread: clinical aspects, 163

McAnalley, B.H. *see* Tizard, I.R., 290
McCall, C.A. *see* Warren, R.P., 145; Warren, R.P., 323
Mai, D. *see* Schulof, R.S., 30
Marshall, G.D. *see* West, W.H., 268
Marth, C., Brattia, M., Müller-Holzner, E., Mayer, I., Zech, J., Tabarelli, M. and Daxenbichler, G.: Modulation of secretion of human chorionic gonadotropin by biologic response modifiers on term placenta and choriocarcinoma cells, 140
Mayer, I. *see* Marth, C., 140
Mehta, A. *see* Oliver, R.T.D., 14
Miller, H.C. and Vito, C.: Action of a thymic cytokine TslF™ in reversing the autoimmune disease state of the MRL/lpr mouse, 213
Miller, R.M. *see* Oliver, R.T.D., 14
Mills, M. *see* Schulof, R.S., 30
Miyake, Y., Ajitsu, S., Yamashita, T. and Sendo, F.: Enhancement by recombinant interferon-γ of spontaneous tumor cytostasis by human neutrophils, 37
Mizuno, D. *see* Okutomi, T., 275
Morikawa, A. *see* Okutomi, T., 275
Morikawa, K. *see* Hosokawa, M., 74
Mull, R. *see* Bartsch, H.H., 21
Müller-Holzner, E. *see* Marth, C., 140
Murata, J. *see* Saiki, I., 261
Murphy, R.M., Colton, C.K. and Yarmush, M.L.: Staphylococcal protein A adsorption in neoplastic disease: analysis of physicochemical aspects, 186

Nagel, G.A. *see* Bartsch, H.H., 21
Nayak, S.K. *see* Lewko, W.M., 256
Nelson, A. *see* Schulof, R.S., 30
Nerkar, D.P. and Gangadharan, M.: Modification of L-asparaginase from *Erwinia carotovora* using human serum albumin, 152

Nochomovitz, L.E. *see* Schulof, R.S., 30
Nottrott, S. *see* Schütze, S., 96

Ogden, J. *see* Dillman, R.O., 250; Oldham, R.K., 103; Orr, D., 229
Ogden, J.R., Leung, K., Kunda, S.A., Telander, M.W., Avner, B.P., Liao, S-K, Thurman, G.B. and Oldham, R.K.: Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an N-hydroxysuccinimide active ester intermediate of *cis*-aconityl-doxorubicin: preparation and *in vitro* cytotoxicity, 170
Ohnishi, H. *see* Chao, T-Y, 318
Okinaga, S. *see* Okutomi, T., 275
Okutomi, T., Dobashi, K., Takano, E., Nishizawa, T., Morikawa, A., Oshima, H., Soma, G-I, Mizuno, D., Seto, T., Hirata, S., Ajika, K., Okinaga, S. and Kiyoshi, A.: Immunohistochemical evidence for the production of tumor necrosis factor by murine MH134 tumor cells as well as monocytes in tumor lesions after systemic administration of a polyalcoholized mannoglucan from *Microcellobosporia grisea*, 275
Oldham, R.K.: Commentary: Regulatory hierarchies, 3; Clinical research in cancer: a time for consensus, 242; *see* Orr, D., 229; Gazitt, Y., 328; Lewko, W.M., 256; Ogden, J.R., 170; West, W.H., 268
Oldham, R.K., Lewis, M., Orr, D.W., Avner, Barry, Liao, S-K, Ogden, J.R., Avner, Belina and Birch, R.: Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies, 103
Oliver, R.T.D., Miller, R.M., Mehta, A. and Barnett, M.J.: A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression, 14
Oliver, R.T.D., Stephenson, C., Collino, C.E. and Parkinson, M.C.: Clinicopathological significance of immunoreactive beta-hCG production by bladder cancer, 43
Orr, D. *see* West, W.H., 268; Oldham, R.K., 103
Orr, D., Oldham, R., Lewis, M., Ogden, J., Liao, S-K, Leung, K., Dupere, S., Birch, R. and Avner, Belina: Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies, 229
Oshima, H. *see* Okutomi, T., 275

Parkinson, M.C. *see* Oliver, R.T.D., 43
Paxton, H.M. *see* Schulof, R.S., 30
Pettengill, O.S., Lewko, W.M.: Cell culture of human metastatic breast carcinomas: a review, 122
Pfizenmaier, K. *see* Bartsch, H.H., 21; Schütze, S., 96
Prokop, A.: An integration of cultivation and purification in membrane bioreactors: production of monoclonal antibodies and lymphokines by microencapsulated hybridomas, 61

Rakovsky, E. *see* Lurie, H., 163
Rinehart, J.J., Geidenberger, C. and Aldrich, W.: Separation of lymphokine-activated killer cell precursors and T-cells: differential growth characteristics and apparent lack of a T-cell suppressor of LAK-cell induction, 133
Romano, P.J., Lipton, A., Harvey, H.A., Bartholomew, M.J., Guidice, G., Kloszewski, F., Witkowski, L. and Downing, M.R.: Immunologic monitoring studies in advanced cancer patients treated with recombinant human gamma interferon (IFN-γ_{4A}), 208

Saiki, I., Murata, J., Saito, S., Higashi, N. and Azuma, I.: Effect of systemic administration of mouse recombinant interferon-γ on the lung tumor metastases in mice, 261
Saito, S. *see* Saiki, I., 261
Sakurai, F. *see* Satomi, N., 155
Sarzotti, M. *see* Stanton, G.J., 305
Satomi, N., Sakurai, A., Iimura, F., Haranaka, R. and Haranaka, K.: Japanese modified traditional Chinese medicines as preventive drugs of the side effects induced by tumor necrosis factor and lipopolysaccharide, 155
Schade, S.G. *see* Cohen, E.P., 86
Scheurich, P. *see* Schütze, S., 96
Schulof, R.S., Mai, D., Nelson, A., Paxton, H.M., Cox, J.W., Jr., Turner, M.L., Mills, M., Hix, W.R., Nochomovitz, L.E., Peters, L.C. and Hanna, M.G., Jr.: Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer, 30
Schütze, S., Nottrott, S., Scheurich, P., Kronke, M. and Pfizenmaier, K.: Mechanisms of TNF resistance: identification of membrane phosphoproteins associated with a dominant resistant phenotype in lymphoid-myeloid somatic cell hybrids, 96
Sendo, F. *see* Miyake, Y., 37
Seto, T. *see* Okutomi, T., 275
Shawler, D.L. *see* Dillman, R.O., 46
Soma, G-I. *see* Okutomi, T., 275
Stanton, G.J., Lloyd, R.E., Sarzotti, M. and Blalock, J.E.: Protection of mice from Semliki Forest virus infection by lymphocytes treated with low levels of interferon, 305
Stephenson, C. *see* Oliver, R.T.D., 43

Tabarelli, M. *see* Marth, C., 140
Takano, E. *see* Okutomi, T., 275
Takashi, N. *see* Okutomi, T., 275
Tauer, K.W. *see* West, W.H., 268
Telander, M.W. *see* Ogden, J.R., 170
Thurman, G.B. *see* Gazitt, Y., 297; Lewko, W.M., 256; Ogden, J.R., 170
Tizard, I.R., Carpenter, R.H., McAnalley, B.H. and Kemp, M.C.: The biological activities of mannans and related complex carbohydrates, 290
Turner, M.L. *see* Schulof, R.S., 30

Urban, R.W. *see* Warren, R.P., 145; Warren, R.P., 323

Vito, C. *see* Miller, H.C., 213

Warren, R.P., McCall, C.A. and Urban, R.W.: Augmentation of natural killer cell activity by ImuVert: a biological response modifier derived from *Serratia marcescens*, 145
Warren, R.P., McCall, C.A., Urban, R.W.: Augmentation of ADCC and Cytotoxic T-cell Activity with ImuVert, 323
West, W.H., Tauer, K.W., Yanelli, J.R., Marshall, G.D., Orr, D., Lewis, M., Birch, R. and Oldham, R.K.: Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma, 268
Wimer, B.M.: The ideal biological response modifier, 311
Witkowski, L. *see* Romano, P.J., 208

Xu, Z-y. *see* Hosokawa, M., 74

Yamashita, T. *see* Miyake, Y., 37
Yannelli, J.R. *see* West, W.H., 268
Yarmush, M.L. *see* Murphy, R.M., 186

Zech, J. *see* Marth, C., 140

Subject Index

Active specific immunotherapy, 30
Acute myeloid leukemia, 86
Adherent, 328
Adoptive mononuclear cell therapy, 311
Adoptive transfer assay, 223
Adriamycin, 103
Alveolar macrophage, 261
Anaphylaxis, 81
Antibody cocktails, 229
Antibody-dependent cell-mediated cytotoxicity, 323
Antinuclear antibody, 213
Antitumor polysaccharide, 275
Arachidonic cascade, 155
Autologous tumor, 30

Beta-hCG, 43
Biological response modifier, 140, 311

Biotherapy, 7, 256
Bladder cancer, 43
Bleomycin, 74
Bulgaricus effect, 279

Cell culture, 122
Cell-mediated cytotoxicity, 244
Chemosensitivity, 256
Chinese medicines, 155
Cholesterol, 290
Choriocarcinoma, 140
Chronic lymphocytic leukemia, 328
Cis-aconitate, 170
Clinical toxicity, 21
Continuous cell lines, 122
Cytogenetic studies, 328
Cytostasis, 37
Cytotoxic T-cell activity, 323

Delayed-type skin tests, 30
Doxorubicin, 170

Epstein-Barr virus negative malignant lymphoid cell line, 328
Erwinia carotovora, 152
Extracorporeal devices, 186

Hematologic parameters, 21
HLA typing, 86
Human chorionic gonadotropin, 140
Human monoclonal antibodies, 7
Human serum albumin, 152
Hybrid cells, 86
Hybridomas, 61

N-hydroxysuccinimide, 170

Idiotypic Ig, 297
IL-1, 297
IL-2, 297
Immune complexes, 186
Immunizations, 86
Immunoadsorption, 186
Immunoaugmentation, 74
Immunoconjugate cocktails, 103
Immunoconjugates, 170, 229
Immunocytochemistry, 43
Immunomodulation *in vivo*, 21
Immunomodulator, 145, 323
Immunosensitivity, 74
Indomethacin, 318
Induction, 297
Infusion, 268
Interferon, 37, 305
Interferon-lymphocyte subpopulations, 208
Interleukin-2, 133, 268, 318
Intracavitary lymphocytes, 163
Intraperitoneal challenge, 223
L4 isolectin, 311

Large granular lymphocytes, 133
L-Asparaginase, 152
L. bulgaricus, 279
Leukemia, 297
Leukemia-derived, 86
Leukemic cell hybrids, 96
Lewis lung carcinoma, 261
Lipopolysaccharide, 155
B-lymphocytes, 244
T-lymphocytes, 244
Lymphokine-activated killer cells, 133, 163, 318
Lymphokines, 61
Lymphoma, 297

Macrophages, 244, 290
Mammary carcinoma, 122
Mannans, 290
Mathematical modeling, 46
B16 melanoma, 218, 261
Metastatic renal carcinoma, 268
Metastatic tumor, 122
3-methylcholanthrene, 223
Microcapsules, 61
Mitogenic lectins, 311
Mitomycin C, 229
Monoclonal antibodies, 61, 81, 170
Monoclonal antibody, 46, 223
Mouse leukemia, 279
MRL/lpr mice, 213
Myeloid-associated antigens, 86

Natural killer cells, 145, 208
Neoplastic disease, 186
Non-small cell lung cancer, 30

Oncofetal antigen, 223

Peritoneal exudate cells, 74
Pharmokinetics, 46
Phosphoprotein pattern, 96
Phytohemagglutinin, 311
Placenta, 140
PMN, 37
Primary tumor, 122
Process limiting phenomena, 61
Protection, 305
Pulmonary metastases, 261

Recombinant interferon-γ, 261
Recombinant interleukin-2, 163
Renal cell carcinoma, 14
Rheumatoid factor, 213

Semliki forest virus, 305
Serratia marcescens, 145, 323
Serum free medium, 122
Spontaneous regression, 14
Staphylococcal protein A, 186
Suppressor cells, 74, 133

Targeted cancer therapy, 103
T-cells, 133
Therapy of metastases, 14
Tissue culture, 256
TNF alpha-resistance, 96
Triggering agent, 275
TsIF™, 213
Tumor, 37, 244, 290
Tumor-associated transplantation antigen, 223
Tumor necrosis factor, 155, 275
Tumor protective immunity, 218
Tumor response, 21
Tumor-specific transplantation antigen, 223

Vaccine preparation, 218

Xenograft, 256
X-irradiation, 244

Yogurt effect cell response, 279